Novavax NVAX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Novavax's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Novavax's accrued expenses?
- Novavax (NVAX) reported accrued expenses of $132.45M in Q1 2026.
- How has Novavax's accrued expenses changed year-over-year?
- Novavax's accrued expenses decreased by 6.7% year-over-year, from $142.03M to $132.45M.
- What is the long-term trend for Novavax's accrued expenses?
- Over 5 years (2020 to 2025), Novavax's accrued expenses has grown at a 73.1% compound annual growth rate (CAGR), from $8.86M to $137.78M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.